A5008329263- Atrial Fibrillation Management and Outcomes
- Antiplatelet Therapy and Cardiovascular Diseases
- Acute Myocardial Infarction Research
- Venous Thromboembolism Diagnosis and Management
- Cardiac Arrhythmias and Treatments
- Coronary Interventions and Diagnostics
- COVID-19 Clinical Research Studies
- Cardiac Imaging and Diagnostics
- Cardiac electrophysiology and arrhythmias
- COVID-19 and healthcare impacts
- Health Systems, Economic Evaluations, Quality of Life
- Cardiovascular Function and Risk Factors
- Viral Infections and Immunology Research
- Statistical Methods in Clinical Trials
- Cardiac Arrest and Resuscitation
- Cardiac Health and Mental Health
- Acute Ischemic Stroke Management
- Healthcare during COVID-19 Pandemic
- Potassium and Related Disorders
- Membrane-based Ion Separation Techniques
- Heart Failure Treatment and Management
- Long-Term Effects of COVID-19
- Cardiac Structural Anomalies and Repair
- Cardiomyopathy and Myosin Studies
- SARS-CoV-2 and COVID-19 Research
Hospital Israelita Albert Einstein
2021-2025
Clinical Research Institute
2015-2024
Duke University
2015-2024
Universidade de São Paulo
2020-2024
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2017-2024
Associação Fundo de Incentivo à Pesquisa
2023
Beneficência Portuguesa de São Paulo
2021
Hospital Samaritano de São Paulo
2019-2021
Hospital São Paulo
2019-2020
Instituto do Câncer do Estado de São Paulo
2020
BackgroundThe efficacy and safety of tofacitinib, a Janus kinase inhibitor, in patients who are hospitalized with coronavirus disease 2019 (Covid-19) pneumonia unclear.MethodsWe randomly assigned, 1:1 ratio, adults Covid-19 to receive either tofacitinib at dose 10 mg or placebo twice daily for up 14 days until hospital discharge. The primary outcome was the occurrence death respiratory failure through day 28 as assessed use an eight-level ordinal scale (with scores ranging from 1 8 higher...
Background The optimal anticoagulation strategy for patients with atrial fibrillation (AF) and bioprosthetic valve (BPV) replacement or native repair remains uncertain. Hypothesis We evaluated the safety efficacy of apixaban vs warfarin in AF a history BPV repair. Methods Using data from Apixaban Reduction Stroke Other Thromboembolic Events Atrial Fibrillation (ARISTOTLE) (n = 18 201), randomized trial comparing AF, we analyzed subgroup 251) prior surgery. contacted sites by telephone to...
Mineralocorticoid receptor antagonists (MRA) improve outcomes in patients with heart failure and reduced ejection fraction (HFrEF) but are underused clinical practice. Observational data suggest that hyperkalemia is the leading obstacle for suboptimal use of MRA.
Pragmatic clinical trial designs have proposed the use of medical claims data to ascertain events; however, accuracy billed diagnoses in identifying potential events is unclear.To compare 1-year cumulative incidences when were identified by vs physician adjudication and assess bill-identified using as criterion standard.This post hoc analysis a assessed forms records for all rehospitalizations at 233 US hospitals within 1 year index acute myocardial infarction (MI) 12 365 patients enrolled...
To investigate the association between pericoronary adipose tissue (PCAT) computed tomography (CT) attenuation derived from coronary angiography (CTA) and flow reserve (CFR) by positron emission (PET) in patients with suspected artery disease (CAD).PCAT CT was measured proximal segments of all major epicardial vessels 105 CAD. We evaluated relationship PCAT other quantitative/qualitative CT-derived anatomic parameters CFR PET. Overall, mean age 60 ± 12 years 93% had intermediate pre-test...
Mineralocorticoid receptor antagonists (MRAs) improve outcomes in patients with heart failure and reduced ejection fraction (HFrEF). However, MRAs are often underused because of hyperkalemia concerns.
Few data exist on regional systems of care for the treatment ST-segment-elevation myocardial infarction (STEMI) in developing countries. Our objective was to describe temporal trends 30-day mortality and identify predictors among STEMI patients enrolled a prospective registry Brazil.
Resumo O desafio imposto ao sistema de saúde pela pandemia da COVID-19 faz com que haja uma necessidade readequações rotinas e serviços saúde, os objetivos controlar a disseminação do vírus preservar saúde. Torna-se ainda mais importante o manejo seguro correto dos pacientes grupos risco, como idosos, portadores doenças cardiovasculares câncer. Dessa forma, cardio-oncologia ganha novo dimensionamento, no intuito se adequar [...]
Greater understanding of differences between men and women with coronary heart disease is needed.In this post hoc analysis the STABILITY (Stabilization Atherosclerotic Plaque by Initiation Darapladib Therapy) trial, we described psychosocial factors, treatments, outcomes versus stable explored association sex characteristics cardiovascular risk. Cox proportional hazards models were used to assess relationship outcomes. Interactions among sex, composite death, nonfatal myocardial infarction,...
Dual antiplatelet therapy (DAPT) is currently the standard of care after percutaneous coronary intervention (PCI). Recent studies suggest that reducing DAPT to 1-3 months followed by an aspirin-free single (SAPT) strategy with a potent P2Y
The geographical disparity in the pathophysiological pattern of coronary artery disease (CAD) among patients undergoing percutaneous intervention (PCI) is unknown.
Abstract Objectives We aimed to explore angiographic patterns and in‐hospital outcomes of patients with concomitant coronavirus disease‐19 (COVID‐19) myocardial infarction (MI). Background Patients COVID‐19 may experience MI during the course viral infection. However, this association is currently poorly understood. Methods This a multicenter prospective study consecutive who underwent coronary angiography. Quantitative qualitative angiography were analyzed by two observers in an independent...